Ignite Creation Date:
2024-05-06 @ 3:52 AM
Last Modification Date:
2024-10-26 @ 11:40 AM
Study NCT ID:
NCT02395601
Status:
COMPLETED
Last Update Posted:
2022-05-18
First Post:
2015-03-10
Brief Title:
A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas
Sponsor:
Constellation Pharmaceuticals
Organization:
Constellation Pharmaceuticals
Study Overview
Official Title:
A Phase 1 Study of CPI-1205 a Small Molecule Inhibitor of EZH2 in Patients With B-Cell Lymphomas
Status:
COMPLETED
Status Verified Date:
2022-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
First in human open-label sequential dose escalation and expansion study of CPI-1205 in patients with progressive B-cell lymphomas CPI-1205 is a small molecule inhibitor of EZH2
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None